Zobrazit minimální záznam

Correlation of genotype, phenotype and mitochondrial metabolism of patients with Friedreich's ataxia with the aim of implementing innovative therapies

dc.contributor.authorŠťovíčková, Lucie
dc.contributor.authorHansíková, Hana
dc.contributor.authorHadžić, Haris
dc.contributor.authorStrnad, Pavel
dc.contributor.authorNovotná, Ludmila
dc.contributor.authorŠimčík, Martin
dc.contributor.authorMušová, Zuzana
dc.contributor.authorVyhnálek, Martin
dc.contributor.authorPaulasová - Schwabová, Jaroslava
dc.contributor.authorZumrová, Alena
dc.date.accessioned2024-09-10T18:15:29Z
dc.date.available2024-09-10T18:15:29Z
dc.date.issued2022
dc.identifier.urihttps://hdl.handle.net/20.500.14178/2607
dc.description.abstractTitle: Presentation of a cohort of 40 Czech and Slovak patients with Friedreich's ataxia with the aim of introducing innovative therapiesBackground and objectives: Friedreich's ataxia (FA) is an autosomal recessive inherited disease caused by a mutation in the FXN gene for the mitochondrial protein frataxin. As a result of its dysfunction, both neurological symptoms and non-constant damage to other tissues or organs are manifested. Since 1999, 76 genetically confirmed Czech and Slovak patients have been examined at the Center of Hereditary Ataxia in Prague (40 active; 20 died; 16 lost in follow-up). Our aim was to correlate clinical data monitoring the natural course of the disease with metabolic and genetic markers in order to prepare for the application of targeted biological / gene therapies.Methods: Patients with genetically confirmed FA were neurologically examined and underwent clinical assessment including the Scale for the Assessment and Rating of Ataxia (SARA); Activities of Daily Living (ADL); Inventory of Non-Ataxia Signs (INAS); Spino-Cerebellar Ataxia Functional Index (SCAFI); Montreal Cognitive Assessment (MoCA); quality of life assessments; neurocognitive tests; and specific laboratory tests including biosampling, mitochondrial function in isolated platelets (spectrophotometry method) and genetic analysis of the FXN gene by determining the length of GAA expansions (long-range polymerase chain reaction (PCR) with PCR product analysis on an Agilent 4200 TapeStation system).Results: A total of 40 patients with FA were examined with a comprehensive protocol in the period 08/2021 to 06/2022 and their data were entered into the EFACTS registry (European Friedreich's Ataxia Consortium for Translational Studies). Their mean age was 32.3 (8-72) years (6 of them under 18), 22 male / 18 female; average ADL 15.4 (2-27) out of 36 total; average SARA 22.6 (7-40) out of 40 total. The activity of respiratory chain complexes in isolated platelets in 26 patients with Friedreich's ataxia and controls shows decreased cytochrome c oxidase (COX) activity and decreased COX / CS (CS - citrate synthase) ratio.Conclusion: We present a well-defined cohort of Czech patients with FA, which has recently been included in the EFACTS registry and is ready for clinical trials. Further biochemical analysis and longitudinal follow-up is ongoing.en
dc.language.isoen
dc.relation.urlhttps://eveeno.com/agiconference2022
dc.rightsPlný text výsledku je zpřístupněn v repozitáři pouze přihlášeným uživatelům Univerzity Karlovy, pouze pro čtení. Dále lze plné texty z repozitáře stahovat, případně tisknout, ale pouze pro osobní potřebu (viz § 30 zákona č. 121/2000 Sb., autorského zákona).cs
dc.rightsThe fulltext is published in the repository only for authenticated Charles University users as read-only. Authenticated Charles University users are entitled to download and print the fulltext published without a licence for their personal use only (in accordance with § 30 of Act No. 121/2000 Coll., the Copyright Act).en
dc.titleCorrelation of genotype, phenotype and mitochondrial metabolism of patients with Friedreich's ataxia with the aim of implementing innovative therapiesen
dcterms.accessRightsrestrictedAccess
dc.date.updated2024-09-10T18:15:28Z
dc.subject.keywordFriedreich’s ataxiaen
dc.subject.keywordgenotypeen
dc.subject.keywordphenotypeen
dc.subject.keywordmitochondrial metabolismen
dc.subject.keywordcytochrome c oxidase (COX)en
dc.subject.keywordcitrate synthase (CS)en
dc.subject.keywordNADH-decylubiquinone oxidoreductase (NQR), succinate decylubiquinone DCPIP reductase (SQR)en
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/UK/GAUK/GAUK309121
dc.relation.fundingReferenceinfo:eu-repo/grantAgreement/MSM//LX22NPO5107
dc.date.embargoStartDate2024-09-10
dc.date.embargoEndDate2023-01-01
dc.contributor.organizerAtaxia Global Ïnitiative
dc.type.obd81
dc.type.versioninfo:eu-repo/semantics/acceptedVersion
dc.identifier.obd625648
dc.subject.rivPrimary30000::30100::30103
dc.subject.rivSecondary30000::30100
uk.faculty.primaryId109
uk.faculty.primaryName2. lékařská fakultacs
uk.faculty.primaryNameSecond Faculty of Medicineen
uk.faculty.secondaryId108
uk.faculty.secondaryId53
uk.faculty.secondaryId52
uk.faculty.secondaryName1. lékařská fakultacs
uk.faculty.secondaryNameFirst Faculty of Medicineen
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazecs
uk.faculty.secondaryNameVšeobecná fakultní nemocnice v Prazeen
uk.faculty.secondaryNameFakultní nemocnice v Motolecs
uk.faculty.secondaryNameMotol University Hospitalen
uk.department.primaryId1677
uk.department.primaryNameKlinika dětské neurologiecs
uk.department.primaryNameKlinika dětské neurologieen
uk.department.secondaryId109
uk.department.secondaryId1522
uk.department.secondaryId100010693809
uk.department.secondaryId100010692538
uk.department.secondaryId5000002603
uk.department.secondaryId100010692569
uk.department.secondaryId1682
uk.department.secondaryName2. lékařská fakultacs
uk.department.secondaryNameSecond Faculty of Medicineen
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1. LF a VFNcs
uk.department.secondaryNameDepartment of Paediatrics and Inherited Metabolic Disorders 1. LF UK a VFNen
uk.department.secondaryNameÚstav biologie a lékařské genetiky 2. LF UK a FN Motolcs
uk.department.secondaryNameDepartment of Biology and Medical Genetics, 2nd Faculty of Medicine and Motol University Hospitalen
uk.department.secondaryNameKlinika dětské neurologie 2. LF UK a FN Motolcs
uk.department.secondaryNameDepartment of paediatric Neurology, 2nd Faculty of Medicine and Motol University Hospitalen
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1.LF a VFNcs
uk.department.secondaryNameKlinika pediatrie a dědičných poruch metabolismu 1.LF a VFNen
uk.department.secondaryNameNeurologická klinika 2. LF UK a FN Motolcs
uk.department.secondaryNameDepartment of Neurology, 2nd Faculty of Medicine and Motol University Hospitalen
uk.department.secondaryNameNeurologická klinikacs
uk.department.secondaryNameDepartment of Neurologyen
uk.event.nameAtaxia Global Conference 2022
dc.type.obdHierarchyCsPŘEDNÁŠKA, POSTER::přednáška nebo poster::postercs
dc.type.obdHierarchyEnLECTURE, POSTER::lecture or poster::posteren
dc.type.obdHierarchyCode81::145::340en
uk.displayTitleCorrelation of genotype, phenotype and mitochondrial metabolism of patients with Friedreich's ataxia with the aim of implementing innovative therapiesen


Soubory tohoto záznamu

Thumbnail

Tento záznam se objevuje v následujících kolekcích

Zobrazit minimální záznam